Literature DB >> 16864027

Clinical biology and surgical therapy of intramucosal adenocarcinoma of the esophagus.

Daniel S Oh1, Jeffrey A Hagen, Parakrama T Chandrasoma, Christy M Dunst, Steven R Demeester, Mohammad Alavi, Cedric G Bremner, John Lipham, Christian Rizzetto, Richard Cote, Tom R Demeester.   

Abstract

BACKGROUND: Mucosal ablation and endoscopic mucosal resection have been proposed as alternatives to surgical resection as therapy for intramucosal adenocarcinoma (IMC) of the esophagus. Acceptance of these alternative therapies requires an understanding of the clinical biology of IMC and the results of surgical resection modified for treatment of early disease. STUDY
DESIGN: Retrospective review of 78 patients (65 men, 13 women; median age 66 years) with IMC who were treated with progressively less-extensive surgical resections (ie, en bloc, transhiatal, and vagal-sparing esophagectomy) from 1987 to 2005.
RESULTS: The tumor was located in a visible segment of Barrett's esophagus in 65 (83%) and in cardia intestinal metaplasia in 13 (17%). A visible lesion was present in 53 (68%) and in all but 4 the lesion was cancer. In those patients with visible Barrett's, the tumor was within 3 cm of the gastroesophageal junction in 66% and within 1 cm in 37%. Esophagectomy was en bloc in 23, transhiatal in 31, vagal-sparing in 20, and transthoracic in 4. Operative mortality was 2.6%. Vagal-sparing esophagectomy had less morbidity, a shorter hospital stay, and no mortality. Of the patients who had en bloc resection, a median of 41 nodes were removed. One patient had one lymph node metastasis on hematoxylin and eosin staining and two others, normal on hematoxylin and eosin staining, had micrometastases on immunohistochemistry. Actuarial survival at 5 years was 88% and was similar for all types of resections. Two patients died from systemic metastases and seven from noncancer causes.
CONCLUSIONS: IMC occurred in cardia intestinal metaplasia and in Barrett's esophagus. Two-thirds of patients with IMC had a visible lesion. Most tumors occurred near the gastroesophageal junction. Node metastases were uncommon, questioning the need for lymphadenectomy. A vagal-sparing technique had less morbidity than other forms of resection and no mortality. Survival after all types of resection was similar. Outcomes of endoscopic techniques should be compared with this benchmark.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16864027     DOI: 10.1016/j.jamcollsurg.2006.05.006

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  26 in total

Review 1.  Barrett's esophagus with high-grade dysplasia: focus on current treatment options.

Authors:  Leonidas Lekakos; Nikolaos P Karidis; Dimitrios Dimitroulis; Christos Tsigris; Gregory Kouraklis; Nikolaos Nikiteas
Journal:  World J Gastroenterol       Date:  2011-10-07       Impact factor: 5.742

Review 2.  Guidelines for surgical treatment of gastroesophageal reflux disease.

Authors:  Dimitrios Stefanidis; William W Hope; Geoffrey P Kohn; Patrick R Reardon; William S Richardson; Robert D Fanelli
Journal:  Surg Endosc       Date:  2010-08-20       Impact factor: 4.584

3.  Esophagus: How should early neoplasia in Barrett esophagus be treated?

Authors:  Oliver Pech
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-04       Impact factor: 46.802

4.  Barrett's adenocarcinoma with esophageal varices successfully treated by endoscopic submucosal dissection with direct varices coagulation.

Authors:  Chise Ueda; Tetsuya Yosizaki; Norio Katayama; Norihiro Okamoto; Hiroki Hashimura; Masanori Matsumoto; Megumi Takagi; Seitaro Ikeoka; Kenji Momose; Takaaki Eguchi; Hiroshi Yamashita; Akihiko Okada
Journal:  Clin J Gastroenterol       Date:  2019-09-26

Review 5.  American Gastroenterological Association technical review on the management of Barrett's esophagus.

Authors:  Stuart J Spechler; Prateek Sharma; Rhonda F Souza; John M Inadomi; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2011-03       Impact factor: 22.682

Review 6.  [Surgical strategy for early stage carcinoma of the esophagus].

Authors:  N Niclauss; M Chevallay; J L Frossard; S P Mönig
Journal:  Chirurg       Date:  2018-05       Impact factor: 0.955

7.  Depth of submucosal tumor infiltration and its relevance in lymphatic metastasis formation for T1b squamous cell and adenocarcinomas of the esophagus.

Authors:  Michael F Nentwich; Katharina von Loga; Matthias Reeh; Faik G Uzunoglu; Andreas Marx; Jakob R Izbicki; Dean Bogoevski
Journal:  J Gastrointest Surg       Date:  2013-10-04       Impact factor: 3.452

8.  Evolving changes in the management of early oesophageal adenocarcinoma in a tertiary centre.

Authors:  N J O'Farrell; J V Reynolds; N Ravi; J O Larkin; V Malik; G F Wilson; C Muldoon; D O'Toole
Journal:  Ir J Med Sci       Date:  2012-12-16       Impact factor: 1.568

Review 9.  Reflux esophagitis, high-grade neoplasia, and early Barrett's carcinoma-what is the place of the Merendino procedure?

Authors:  A H Hölscher; D Vallböhmer; C Gutschow; E Bollschweiler
Journal:  Langenbecks Arch Surg       Date:  2008-11-07       Impact factor: 3.445

10.  Minimally invasive esophagectomy.

Authors:  Christy M Dunst; Lee L Swanström
Journal:  J Gastrointest Surg       Date:  2009-09-30       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.